Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis

The role of [-2]proPSA (p2PSA) based diagnostic tests for the detection of aggressive prostate cancer (PCa) has not been fully evaluated. We conducted a meta-analysis to evaluate the diagnostic performance of p2PSA/free PSA (%p2PSA) and prostate health index (Phi) tests for PCa and to evaluate their ability in discriminating between aggressive and non-aggressive PCa. A total of 16 articles were included in this meta-analysis. For the detection of PCa, the pooled sensitivity, specificity, and AUC were 0.86 (95% CI, 0.84–0.87), 0.40 (95% CI, 0.39–042) and 0.72 (95% CI, 0.67–0.77) for %p2PSA respectively, and were 0.85 (95% CI, 0.83–0.86), 0.45 (95% CI, 0.44–0.47) and 0.70 (95% CI = 0.65–0.74) for Phi, respectively. In addition, the sensitivity for discriminating PCa between higher Gleason score (≥7) and lower Gleason score (<7) was 0.96 (95% CI, 0.93–0.98) and 0.90 (95% CI, 0.87–0.92) for %p2PSA and Phi respectively, and the specificity was low, only 0.09 (95% CI, 0.06–0.12) and 0.17 (95% CI, 0.14–0.19) for %p2PSA and Phi, respectively. Phi and %p2PSA have a high diagnostic accuracy rates and can be used in PCa diagnosis. Phi and %p2PSA may be useful as tumor markers in predicating patients harboring more aggressive disease and guiding biopsy decisions.